Now, there’s new hope for professionals involved in treating the Epstein-Barr virus. EBV can have long-term effects on the human body. Its name is among the most common human viruses. Once an EBV infection occurs, the virus becomes dormant in the human body after treatment. However, it may reactivate in many cases. In fact, the virus is the primary cause of critical illnesses such as infectious mononucleosis. In addition, the virus is closely associated with some forms of cancers, including Hodgkin lymphoma.
Here’s the latest information about the EBV. A panel of mAbs (investigational monoclonal antibodies) targeting various EBV sites could prevent infection when tested in human bodies within a laboratory environment. In fact, one of the mAbs was able to extend almost total protection from the EBV infection. In addition, the experimental mAb could also offer protection from lymphoma when used in mice.
Scientists from the NIAID (National Institute of Allergy and Infectious Diseases) and researchers part of the Walter Reed Army Institute of research led the study. Additional research on mAb769B10 is possible, say researchers associated with the investigation.
The study highlights manageable EBV vaccine targets and the possibility of using these mAbs in combination or alone to prevent or deal with EBV infection in immunocompromised patients. Here the reference is toward patients who are more susceptible to severe EBV -related disease.
The findings of the study are available online in the journal Immunity.
The EBV is an example of the herpes virus, also known as HHV 4. The most commonly observed symptom of HHV-4 is glandular fever. However, many associates the EBV infection with several autoimmune conditions such as the dermatomyositis, multiple sclerosis, and rheumatoid arthritis.